Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
15.94 USD | -2.03% | -4.09% | -5.18% |
Financials (USD)
Sales 2024 * | 464M | Sales 2025 * | 553M | Capitalization | 1.88B |
---|---|---|---|---|---|
Net income 2024 * | 138M | Net income 2025 * | 186M | EV / Sales 2024 * | 3.06 x |
Net cash position 2024 * | 459M | Net cash position 2025 * | 682M | EV / Sales 2025 * | 2.16 x |
P/E ratio 2024 * |
13.7
x | P/E ratio 2025 * |
10.4
x | Employees | 167 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.59% |
Latest transcript on Catalyst Pharmaceuticals, Inc.
1 day | -2.03% | ||
1 week | -4.09% | ||
Current month | -0.56% | ||
1 month | +9.48% | ||
3 months | -7.33% | ||
6 months | +33.50% | ||
Current year | -5.18% |
Managers | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Richard Daly
CEO | Chief Executive Officer | 62 | 15-02-18 |
Michael Kalb
DFI | Director of Finance/CFO | 53 | Dec. 31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Patrick McEnany
FOU | Founder | 77 | 01-12-31 |
Donald Denkhaus
BRD | Director/Board Member | 78 | 15-02-18 |
David Tierney
BRD | Director/Board Member | 60 | 02-09-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.05% | 29 M€ | +0.33% | ||
0.32% | 26 M€ | +0.78% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-03-28 | 15.94 | -2.03% | 1,172,375 |
24-03-27 | 16.27 | +3.30% | 1,471,658 |
24-03-26 | 15.75 | -0.69% | 828,267 |
24-03-25 | 15.86 | +0.83% | 1,085,212 |
24-03-22 | 15.73 | -5.35% | 948,460 |
Delayed Quote Nasdaq, March 28, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.18% | 1.88B | |
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-9.42% | 16.48B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B |